Accessing antiretroviral therapy following release from prison
- PMID: 19244192
- PMCID: PMC2936238
- DOI: 10.1001/jama.2009.202
Accessing antiretroviral therapy following release from prison
Abstract
Context: Interruption of antiretroviral therapy (ART) during the first weeks after release from prison may increase risk for adverse clinical outcomes, transmission of human immunodeficiency virus (HIV), and drug-resistant HIV reservoirs in the community. The extent to which HIV-infected inmates experience ART interruption following release from prison is unknown.
Objectives: To determine the proportion of inmates who filled an ART prescription within 60 days after release from prison and to examine predictors of this outcome.
Design, setting, and participants: Retrospective cohort study of all 2115 HIV-infected inmates released from the Texas Department of Criminal Justice prison system between January 2004 and December 2007 and who were receiving ART before release.
Main outcome measure: Proportion of inmates who filled an ART prescription within 10, 30, and 60 days of release from prison.
Results: Among the entire study cohort (N = 2115), an initial prescription for ART was filled by 115 (5.4%) inmates within 10 days of release (95% confidence interval [CI], 4.5%-6.5%), by 375 (17.7%) within 30 days (95% CI, 16.2%-19.4%), and by 634 (30.0%) within 60 days (95% CI, 28.1%-32.0%). In a multivariate analysis of predictors (including sex, age, race/ethnicity, viral load, duration of ART, year of discharge, duration of incarceration, parole, and AIDS Drug Assistance Program application assistance), Hispanic and African American inmates were less likely to fill a prescription within 10 days (adjusted estimated risk ratio [RR], 0.4 [95% CI, 0.2-0.8] and 0.4 [95% CI, 0.3-0.7], respectively) and 30 days (adjusted estimated RR, 0.7 [95% CI, 0.5-0.9] and 0.7 [95% CI, 0.5-0.9]). Inmates with an undetectable viral load were more likely to fill a prescription within 10 days (adjusted estimated RR, 1.8 [95% CI, 1.2-2.7]), 30 days (1.5 [95% CI, 1.2-1.8]), and 60 days (1.3 [95% CI, 1.1-1.5]). Inmates released on parole were more likely to fill a prescription within 30 days (adjusted estimated RR, 1.3 [95% CI, 1.1-1.6]) and 60 days (1.5 [95% CI, 1.4-1.7]). Inmates who received assistance completing a Texas AIDS Drug Assistance Program application were more likely to fill a prescription within 10 days (adjusted estimated RR, 3.1 [95% CI, 2.0-4.9]), 30 days (1.8 [95% CI, 1.4-2.2]), and 60 days (1.3 [95% CI, 1.1-1.4]).
Conclusion: Only a small percentage of Texas prison inmates receiving ART while incarcerated filled an initial ART prescription within 60 days of their release.
Comment in
-
Treatment for individuals with HIV/AIDS following release from prison.JAMA. 2009 Jul 8;302(2):147-8; author reply 148. doi: 10.1001/jama.2009.920. JAMA. 2009. PMID: 19584342 No abstract available.
-
Treatment for individuals with HIV/AIDS following release from prison.JAMA. 2009 Jul 8;302(2):147; author reply 148. doi: 10.1001/jama.2009.919. JAMA. 2009. PMID: 19584343 No abstract available.
Similar articles
-
Enrollment in outpatient care among newly released prison inmates with HIV infection.Public Health Rep. 2010 Jan-Feb;125 Suppl 1(Suppl 1):64-71. doi: 10.1177/00333549101250S109. Public Health Rep. 2010. PMID: 20408389 Free PMC article.
-
Predictors of reincarceration and disease progression among released HIV-infected inmates.AIDS Patient Care STDS. 2010 Jun;24(6):389-94. doi: 10.1089/apc.2009.0303. AIDS Patient Care STDS. 2010. PMID: 20565323 Free PMC article.
-
Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.Antivir Ther. 2004 Oct;9(5):713-9. Antivir Ther. 2004. PMID: 15535408
-
A systematic review and meta-analyses on initiation, adherence and outcomes of antiretroviral therapy in incarcerated people.PLoS One. 2020 May 18;15(5):e0233355. doi: 10.1371/journal.pone.0233355. eCollection 2020. PLoS One. 2020. PMID: 32421754 Free PMC article.
-
Antiretroviral treatment in correctional facilities.HIV Clin Trials. 2005 Jan-Feb;6(1):25-37. doi: 10.1310/GTQM-QRM1-FDW8-Y2FT. HIV Clin Trials. 2005. PMID: 15765308 Review.
Cited by
-
Antiretroviral outcomes in South African prisoners: a retrospective cohort analysis.PLoS One. 2012;7(3):e33309. doi: 10.1371/journal.pone.0033309. Epub 2012 Mar 21. PLoS One. 2012. PMID: 22470448 Free PMC article.
-
"It's like I was out there by myself": The receipt of reentry support among HIV-infected formerly incarcerated individuals in New York City.Health Justice. 2020 Mar 10;8(1):6. doi: 10.1186/s40352-020-00108-4. Health Justice. 2020. PMID: 32157453 Free PMC article.
-
Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy.Clin Infect Dis. 2011 Oct;53(7):725-31. doi: 10.1093/cid/cir491. Clin Infect Dis. 2011. PMID: 21890777 Free PMC article.
-
The Effect of Patient Navigation on the Likelihood of Engagement in Clinical Care for HIV-Infected Individuals Leaving Jail.Am J Public Health. 2018 Mar;108(3):385-392. doi: 10.2105/AJPH.2017.304250. Epub 2018 Jan 18. Am J Public Health. 2018. PMID: 29345992 Free PMC article. Clinical Trial.
-
Alcohol use disorders and antiretroviral therapy among prisoners in Argentina.Int J Prison Health. 2013;9(1):40-50. doi: 10.1108/17449201311310797. Int J Prison Health. 2013. PMID: 24772187 Free PMC article.
References
-
- Boutwell A, Rich JD. HIV infection behind bars. Clin Infect Dis. 2004;38(12):1761–1763. - PubMed
-
- Dixon PS, Flanigan TP, DeBuono BA, et al. Infection with the human immunodeficiency virus in prisoners: meeting the health care challenge. Am J Med. 1993;95(6):629–635. - PubMed
-
- Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(1):47–58. - PubMed
-
- Springer SA, Pesanti E, Hodges J, Macura T, Doros G, Altice FL. Effectiveness of antiretroviral therapy among HIV-infected prisoners: reincarceration and the lack of sustained benefit after release to the community. Clin Infect Dis. 2004;38(12):1754–1760. - PubMed